Anticancer Effects of Cepharanthine on Human Colon Cancer Cells
ฤทธิ์ต้านมะเร็งของเซฟราเรนทีนต่อเซลล์มะเร็งลำไส้ใหญ่ของมนุษย์

Arkornnut Rattanawong (อากรณัท รัตนวงษ์)* Dr.Wacharee Limpanasithikul (ดร.วัชรี ลิมปนสิทธิกลุก)**
Dr.Piyanuch Wonganan (ดร.ปิยนุช วงศ์อนันต์)***

ABSTRACT
Cyclooxygenase (COX–2) has been found to be overexpressed in various tumors including colorectal cancer. Cepharanthine (CEP), a biscoclaurine alkaloid isolated from Stephania cepharantha Hayata, exhibits anticancer activity against several different types of cancer including oropharynx cancer, leukemia, hepatocarcinoma and cholangiocarcinoma. In this study, we investigated the anticancer effects of diclofenac, celecoxib, berberine, CEP and 5-fluorouracil against a COX-2 positive human colon cancer cell line, HT-29. Of all compounds tested, CEP was the most effective agents for controlling the growth of the cancer cells. CEP could significantly induce colon cancer cell apoptosis and effectively inhibit COX-2 mRNA expression. These findings demonstrated that CEP could potentially be used as a novel anticancer agent for COX-2–positive colon cancer cells.

บทคัดย่อ
มะเร็งหลายชนิดมีการแสดงออกของ COX–2 ที่มากผิดปกติ จากการศึกษาพบว่า cepharanthine (CEP) ซึ่งเป็นสารในกลุ่ม biscoclaurine alkaloid ที่พบได้ในรากของต้น Stephania cepharantha Hayata มีฤทธิ์ต้านมะเร็งหลายชนิด เช่น มะเร็งช่องปากและลำคอ มะเร็งเม็ดเลือดขาว มะเร็งตับ และมะเร็งท่อน้ำดี วัตถุประสงค์ของการทดลองนี้เพื่อศึกษาฤทธิ์ต้านมะเร็งของ diclofenac, celecoxib, berberine, CEP และ 5-fluorouracil ต่อเซลล์ HT-29 ซึ่งเป็นเซลล์มะเร็งลำไส้ใหญ่ที่มีการแสดงออกของ COX–2 จากผลการทดลองแสดงให้เห็นว่า CEP สามารถยับยั้งการเจริญของเซลล์มะเร็งได้ดีกว่า diclofenac, celecoxib, berberine, และ 5-fluorouracil โดย CEPสามารถยับยั้งให้เซลล์มะเร็งตายแบบอะพอพโทสิสและสามารถยับยั้งการแสดงออกของยีน COX–2 การทดลองแสดงให้เห็นว่า CEP อาจจะเป็นยาที่มีประสิทธิภาพในการรักษามะเร็งลำไส้ใหญ่ที่มีการแสดงออกของ COX–2

Keywords: Cepharanthine (CEP), Apoptosis, Colon cancer
ค่าสัคัญ: เซฟราเรนทีน อะพอพโทสิส มะเร็งลำไส้ใหญ่

*Correspondent author: pwonganan@gmail.com
* Student, Master of Pharmacy Program in Pharmacology, Graduate School, Chulalongkorn University
** Assistant Professor, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University
*** Lecturer, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University
Introduction

Colorectal cancer is one of the most common cancers in both men and women [1]. The majority of colorectal carcinomas are adenocarcinomas, which originate from the epithelial cells of the colorectal mucosa. The most common treatment for colorectal cancer is surgical resection, followed by adjuvant therapy with 5-fluorouracil, oxaliplatin, leucovorin or radiation. Although chemotherapy has been widely used, its use is often limited due to drug resistance and serious side effects. Therefore, a novel compound that has potent anticancer activity and minimal side effects is urgently needed.

Evidence has shown that patients with inflammatory bowel diseases including ulcerative colitis (UC) and Crohn’s disease (CD) have a significantly higher risk of developing colorectal cancer [2].

Cyclooxygenase (COX) enzyme has played a key role in the biosynthesis of prostaglandins and thromboxane from arachidonic acid. There are two major COX isoforms, including COX-1 and COX-2. COX-1 is constitutively expressed in many tissues and plays an important role in tissue homeostasis, while COX-2 is induced by inflammatory stimuli and involved in pathological processes [3]. COX-2 overexpression has been detected in 84.9% of colon carcinoma and 57.9% of adenomas, suggesting a critical role of COX-2 in colorectal cancer development [4]. Several studies have found that COX-2 overexpression could increase accumulation of prostaglandins (PGs) particularly, PGE2 which promotes colorectal tumor development by stimulating angiogenesis, cell proliferation and apoptosis evasion. Previous study showed that HT-29 cells overexpressing COX-2 were resistant to apoptotic cell death [5]. Epidemiological studies have been suggested that long-term treatment with aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or selective cyclooxygenase 2 (COX-2) inhibitors may reduce the risk of colorectal cancers [6], suggesting that COX-2 is an important target in the treatment of colorectal cancer.

Cepharanthine (CEP), a natural compound isolated from Stephania cepharantha Hayata possess many pharmacological effects such as anti-inflammation, anti-retrovirus, anti-oxidant and anti-cancer [7]. CEP could inhibit production of pro-inflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6) and nitric oxide via suppressing NF-κB [8]. Many studies also showed that CEP has anticancer activity against several types of cancer such as oropharynx cancer, leukemia, hepatocarcinoma and cholangiocarcinoma [9-11]. It has been reported that CEP inhibit tumor growth through multiple mechanisms, including increasing host immune response [12], inducing cancer cell to undergo apoptosis [13-14] and stimulating cell cycle arrest [15]. Although there were reports regarding to cytotoxicity of CEP against several tumors, the anticancer activity of this compound has not been evaluated in COX-2- positive colon cancer cells.
**Objective of the study**

The aim of this study were to determine anticancer effect of diclofenac, celecoxib, berberine, cepharanthine, and 5-fluorouracil against COX-2-positive HT-29 human colon cancer cells and investigate the mechanism(s) underlying the anticancer effect of cepharanthine.

**Methodology**

**Cell culture**

Human colorectal cancer cell line HT-29 was obtained from American Type Culture Collection (ATCC) (Rockville, MD). The cells were maintained in complete Dulbecco’s modified Eagle’s medium (DMEM) medium supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin at 37°C in 5% CO₂ incubator.

**Cytotoxicity assay**

Cell viability was evaluated by the ability of mitochondrial reductase enzyme in living cells to reduce resazurin into resorufin [16]. Cells were seeded in a 96-well plate at a density 5x10³ cell/well and incubate overnight at 37°C, 5% CO₂. Cells were then treated with berberine, celecoxib, cepharanthine, diclofenac, 5-fluorouracil or 0.2% DMSO (vehicle control) in complete DMEM medium at a concentration of 0.01, 0.1, 1, 10, 50 or 100 µM for 48 hours. Then, 15 µL of resazurin solution (0.05 mg/ml) was added to each well and incubated at 37°C for another 5 hours. The colorimetric was quantified by measuring the absorbance at 570 and 600 nm using a microplate reader (Thermo). The percent of cell viability was calculated using the following equation: (Abs. sample/ Abs. control) x100. The values of half inhibitory concentration (IC₅₀) were calculated using the fitted line by GraphPad prism software.

**Quantitative real time PCR**

HT-29 cells were seeded in a 6-well plate at a density of 5 x10⁵ cell/well and incubated overnight. The culture medium was then replaced with fresh complete medium containing 2.5, 5, 10 or 20 µM CEP and incubated for 6 or 24 additional hours. At the end of treatment, the total RNA was extracted using TRIzol (Invitrogen, USA) and mRNA was reversed transcribed using Improm-II™ Reverse Transcription system (Promega, USA) according to the manufacturers’ instructions. Real-time PCR was carried out using SYBR Green qPCR super mix universal (Invitrogen, USA) with the following primers specific for COX-2: 5’-CCCTG AGCATC TACGGTTTG-3’ (forward), 5’-TCGCATACTCTGTTGTGTTCC-3’ (reverse) and for GAPDH: 5’-AAGG TCGGAGTCAACGGATTTGGT-3’ (forward) and 5’-ATGGCATGGACTGTGGTCATGAGT-3’ (reverse). GAPDH was used as an internal control. DNA amplifications were carried out using a StepOnePlus™ Real-Time PCR with the following cycling conditions: 50°C for 2 min, 95°C for 2 min, and 40 cycles of 95°C for 30s, 60°C for 30s, and 72°C for 30s. The fold change in COX-2 gene expression after CEP treatment normalized to GAPDH and
relative to the expression in vehicle treatment was calculated using the $2^{-\Delta\Delta CT}$ method.

**Apoptosis assay**

HT-29 cells were seeded in a 6-well plate at density of $3 \times 10^5$ cell/well and incubated overnight. The cells were then treated with CEP at different concentrations (2.5, 5, 10 or 20 µM) in culture medium for 24 hours. At the end of treatment, the cells were washed with PBS and harvested by trypsinization and centrifuged at 1500 rpm for 5 min. The cell pellets were washed twice with cold PBS and re-suspended with 100 µl of assay buffer. The cells were then stained with 1 µl Annexin V FIT-C (Invitrogen, USA) and 1 µl of 0.05 µg/ml PI (Santa Cruz Biotechnology, USA) for 15 min at room temperature in dark. The stained cells were analyzed using flow cytometry (BD LSR II, Biosciences). Four populations of cells can be distinguished, including viable cells (annexin V-, PI-), early apoptotic cells (annexin V+, PI-), late apoptotic cells (annexin V+, PI+) and necrotic cell (annexin V-, PI+), which are located in the lower left, lower right, upper right, and upper left quadrants of the cytograms, respectively.

**Statistical analysis**

All data are presented as mean ± standard error of mean (SEM). Statistical analysis of data was performed by one-way analysis of variance (ANOVA) followed by LSD post hoc test using SPSS statistics 21 software. Difference is considered significant if $P \leq 0.05$.

**Results**

**Effect of cepharanthine on the COX-2 mRNA expression in HT-29 cells**

COX-2 has been found to be overexpressed in various tumors including colorectal cancer [17]. Several studies have shown that cepharanthine (CEP) possess anti-inflammatory activity by inhibiting production of pro-inflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6) and nitric oxide [18, 19]. Moreover, it was recently reported that inhibition of COX-2 expression is involved in radio sensitization of CEP in cervical adenocarcinoma cell line [20]. Therefore, the effect of CEP on COX-2 mRNA expression in HT-29 cells was evaluated in this study. We initially determined the basal level of COX-2 mRNA in two human colon cancer cell line, HT-29 and Colo-205 cells. As shown in Figure 1A, COX-2 mRNA was detected only in HT-29 cells. Quantitative real time PCR analysis showed that COX-2 mRNA level in HT-29 cells was 2000 fold higher than that in Colo-205. Treatment with 5 or 10 µM CEP significantly decreased COX-2 mRNA expression level only at 6 h after incubation (p < 0.05) (Figure 1B). We however did not observe any change in COX-2 mRNA level after treatment with CEP at 24 h after incubation (Figure 1B).

**Effect of dilofenac, celecoxib, berberine, cepharanthine, and 5-Fluorouracil on cell viability of HT-29 cells**

We then evaluated anticancer effects of diclofenac (a NSAID), celecoxib (a selective
COX-2 inhibitor), berberine and CEP (alkaloids exhibiting both anti-inflammatory and anticancer activities) and 5-fluorouracil (5-FU) (an anticancer drug) against COX-2-positive HT-29 cells using resazurin assay. At 48 h of treatment, diclofenac at 50 and 100 µg/ml and celecoxib and berberine at 50 and 100 µM significantly inhibited the growth of HT-29 cells (Figure 2A-C) while the cytotoxic effects of CEP and 5-FU were detected at 10-100 µM in a concentration-dependent manner (p< 0.05) (Figure 2D and E). The IC50 value of diclofenac was 71.88 ± 5.04 µg/ml while they were 73.39± 3.58, 6.21± 1.68, and 54.73± 3.86 µM for celecoxib, CEP and 5-FU, respectively, suggesting that CEP exhibits the potent anticancer effect against COX-2-positive human colon cancer cells.

**Effect of cepharanthine on apoptosis induction of HT-29 cells**

Most of the currently chemotherapeutic drugs induce cancer cells to undergo apoptosis. We therefore examined the apoptosis induction effect of cepharanthine in HT-29 cells using annexin V-FITC and PI double staining. At 24 h after incubation, CEP at 2.5, 5, 10 or 20 µM could significantly induce apoptotic cell death in a concentration-dependent manner (Figure 3). Treatment of 20 µM of CEP reduced cell viability about 3 times with respect to the vehicle control group. The number of viable cells were 94.54±1.43% for the vehicle control group and 35.95±5.72% for the 20 µM CEP group. It however should be noted that the percentage of late apoptotic cells are greater than early apoptotic cells. Treatment of CEP at 5, 10 and 20 µM could induce cells to undergo late apoptotic about 11.25±2.66, 30.47±1.68 and 30.36±2.80%, respectively. These results suggest that CEP effectively induced COX-2-positive HT-29 cell death via apoptosis induction.

**Discussion**

It has been that cyclooxygenase (COX)-2 and its product, PGE2, are involved in cell proliferation, angiogenesis, and inflammation, leading to development of many cancers including colorectal cancer [21]. It has been shown that COX-2 mRNA is over-expressed in almost 80% of the colorectal tumors, compared with normal colorectal mucosa [22]. Previous study showed that HT-29 cells overexpressing COX-2 were resistant to apoptotic cell death [5]. In the present study, we therefore investigated the effect of cepharanthine (CEP) on COX-2 expression in HT-29, a COX-2 positive human colon cancer cell line. CEP could significantly inhibit COX-2 mRNA expression (Figure 1). We then evaluated the cytotoxic effects of diclofenac, celecoxib, as well as berberine and CEP against the HT-29 cells. The cytotoxicity of 5-FU, a commonly chemotherapeutic drug used for colon cancer, was also tested. We found that all test agents could effectively inhibit the growth of HT-29 cell in a concentration dependent manner, however, with different potencies (Figure 2). Of five compounds tested, CEP was the most effective anticancer agents against HT-29 cells.
The IC\textsubscript{50} value of CEP was approximately 6 µM which was much more potent than 5-FU, the anticancer agent commonly used for colon cancer. Previously, the anticancer activities of diclofenac and celecoxib, at high doses, were also observed in colon cancer cells. Mechanistic studies indicated that diclofenac exhibited its tumor suppression effect in HCT-116 cell, a colon cancer cell line, by inhibiting Wnt/β-catenine signaling pathway [23] while celecoxib could inhibit COX-2 expression, leading to nuclear accumulation of p53 in HCT-116 and HT-29 cells [24], suggesting different mechanisms underlying anticancer effects of anti-inflammatory drugs. It has been reported that 5-FU and berberine induce cancer cells to undergo apoptosis in a p53-dependent manner [25, 26]. Therefore, it is likely that p53 plays a key role in 5-FU and berberine resistance of HT-29 cells. Besides p53, it was shown that COX-2-derived PGE\textsubscript{2} contributes to acquired resistance of colon cancer cells, SNU-C5, to 5-FU [27]. Thus, it is possible that overexpression of COX-2 may also be involved in resistance of HT-29 cells to 5-FU and the potent anticancer activity of CEP against the HT-29 cells may be associated with COX-2 down-regulation. Moreover, constitutive up-regulation of COX-2 has been found to be related to apoptosis resistance [27]. In the present study, we found that CEP effectively induced apoptotic cell death in HT-29 cells (Figure3). Additional studies to determine whether inhibition of COX-2 is related to anticancer effect of CEP are currently under active investigation in our laboratories. CEP has also shown to induce cancer cells to undergo apoptosis through several mechanisms including i) activating caspase-3 and 9 [11, 14-15], ii) stimulating pro-apoptotic signaling pathways such as JNK, ERK and p38 MAPK [14, 28], and iii) inhibiting expression of anti-apoptotic gene Bcl-x\textsubscript{L} [15]. Therefore, mechanisms other than down-regulating of COX-2 may likely be responsible for the anticancer activity of CEP in HT-29 cells as well.

**Conclusion**

The results in the present study clearly demonstrated that cepharanthine (CEP) has a potent anticancer activity against HT-29 cells, a p53-mutant and COX2-positive human colon cancer cell line. Mechanistic studies indicated that CEP effectively induced HT-29 cells to undergo apoptosis as well as inhibited COX-2 expression. These findings suggest that CEP could potentially be used as a novel anticancer agent for p53-mutant or COX-2-positive colon cancer cells which are commonly resistant to currently chemotherapeutic agent.

**Acknowledgement**

This study was supported by the 90\textsuperscript{th} Anniversary of Chulalongkorn University Fund (Ratchadaphiseksompo Endowment Fund) (AR) and Grants for Development of New Faculty Staff, Ratchadaphiseksompot Endowment Fund, Chulalongkorn University (PW).
References


Figure 1  Effect of CEP on COX-2 mRNA expression in HT-29 cells. Basal level of COX-2 mRNA in HT-29 and Colo-205 were determined using RT-PCR. B) COX-2 mRNA expression in HT-29 cells after treatment with CEP at 2.5, 5, 10 and 20 µM CEP for 6 and 24 h.* $P < 0.05$, **$P < 0.01$ with respect to vehicle control (0.2% DMSO).

Figure 2  Cytotoxic effect of diclofenac, celecoxib, berberine, cepharanthine and 5-fluorouracil against COX2-positive HT-29 human colon cancer cells. The cells were treated with 0.01, 0.1, 1, 10, 50 and 100 µM or µg/ml (for diclofenac) for 48 h. Cell viability was determined using resazurin assay. Each value is expressed as the mean ± SEM. (n=3). ***$P < 0.001$ with respect to vehicle control (0.2% DMSO). Data are representative of three independent experiments.
Figure 3 Apoptotic induction effect of CEP in HT-29 cells. A) Representative cytograms of cell apoptosis analysis of HT-29 cells after treatment with CEP (2.5-20 µM) for 24 h. B) The percentage of different HT-29 cell populations (alive, early and late apoptotic cells) after treatment with CEP. Each value is expressed as mean ± SEM. (n=3). **P<0.01, ***P<0.001 compared to the control late apoptotic cells, ###P<0.001 compared to the control viable cells.